Cargando…
Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule
IMPORTANCE: Adult hearing screening is not routinely performed, and most individuals with hearing loss (HL) have never had their hearing tested as adults. OBJECTIVE: To project the monetary value of future research clarifying uncertainties around the optimal adult hearing screening schedule. DESIGN,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652748/ https://www.ncbi.nlm.nih.gov/pubmed/36367737 http://dx.doi.org/10.1001/jamahealthforum.2022.4065 |
_version_ | 1784828543533842432 |
---|---|
author | Borre, Ethan D. Myers, Evan R. Dubno, Judy R. Emmett, Susan D. Pavon, Juliessa M. Francis, Howard W. Ogbuoji, Osondu Sanders Schmidler, Gillian D. |
author_facet | Borre, Ethan D. Myers, Evan R. Dubno, Judy R. Emmett, Susan D. Pavon, Juliessa M. Francis, Howard W. Ogbuoji, Osondu Sanders Schmidler, Gillian D. |
author_sort | Borre, Ethan D. |
collection | PubMed |
description | IMPORTANCE: Adult hearing screening is not routinely performed, and most individuals with hearing loss (HL) have never had their hearing tested as adults. OBJECTIVE: To project the monetary value of future research clarifying uncertainties around the optimal adult hearing screening schedule. DESIGN, SETTING, AND PARTICIPANTS: In this economic evaluation, a validated decision model of HL (DeciBHAL-US: Decision model of the Burden of Hearing loss Across the Lifespan) was used to simulate current detection and treatment of HL vs hearing screening schedules. Key model inputs included HL incidence (0.06%-10.42%/y), hearing aid uptake (0.54%-8.14%/y), screening effectiveness (1.62 × hearing aid uptake), utility benefits of hearing aids (+0.11), and hearing aid device costs ($3690). Distributions to model parameters for probabilistic uncertainty analysis were assigned. The expected value of perfect information (EVPI) and expected value of partial perfect information (EVPPI) using a willingness to pay of $100 000 per quality-adjusted life-year (QALY) was estimated. The EVPI and EVPPI estimate the upper bound of the dollar value of future research. This study was based on 40-year-old persons over their remaining lifetimes in a US primary care setting. EXPOSURES: Screening schedules beginning at ages 45, 55, 65, and 75 years, and frequencies of every 1 or 5 years. MAIN OUTCOMES AND MEASURES: The main outcomes were QALYs and costs (2020 US dollars) from a health system perspective. RESULTS: The average incremental cost-effectiveness ratio for yearly screening beginning at ages 55 to 75 years ranged from $39 200 to $80 200/QALY. Yearly screening beginning at age 55 years was the optimal screening schedule in 38% of probabilistic uncertainty analysis simulations. The population EVPI, or value of reducing all uncertainty, was $8.2 to $12.6 billion varying with willingness to pay and the EVPPI, or value of reducing all screening effectiveness uncertainty, was $2.4 billion. CONCLUSIONS AND RELEVANCE: In this economic evaluation of US adult hearing screening, large uncertainty around the optimal adult hearing screening schedule was identified. Future research on hearing screening has a high potential value so is likely justified. |
format | Online Article Text |
id | pubmed-9652748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-96527482022-11-28 Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule Borre, Ethan D. Myers, Evan R. Dubno, Judy R. Emmett, Susan D. Pavon, Juliessa M. Francis, Howard W. Ogbuoji, Osondu Sanders Schmidler, Gillian D. JAMA Health Forum Original Investigation IMPORTANCE: Adult hearing screening is not routinely performed, and most individuals with hearing loss (HL) have never had their hearing tested as adults. OBJECTIVE: To project the monetary value of future research clarifying uncertainties around the optimal adult hearing screening schedule. DESIGN, SETTING, AND PARTICIPANTS: In this economic evaluation, a validated decision model of HL (DeciBHAL-US: Decision model of the Burden of Hearing loss Across the Lifespan) was used to simulate current detection and treatment of HL vs hearing screening schedules. Key model inputs included HL incidence (0.06%-10.42%/y), hearing aid uptake (0.54%-8.14%/y), screening effectiveness (1.62 × hearing aid uptake), utility benefits of hearing aids (+0.11), and hearing aid device costs ($3690). Distributions to model parameters for probabilistic uncertainty analysis were assigned. The expected value of perfect information (EVPI) and expected value of partial perfect information (EVPPI) using a willingness to pay of $100 000 per quality-adjusted life-year (QALY) was estimated. The EVPI and EVPPI estimate the upper bound of the dollar value of future research. This study was based on 40-year-old persons over their remaining lifetimes in a US primary care setting. EXPOSURES: Screening schedules beginning at ages 45, 55, 65, and 75 years, and frequencies of every 1 or 5 years. MAIN OUTCOMES AND MEASURES: The main outcomes were QALYs and costs (2020 US dollars) from a health system perspective. RESULTS: The average incremental cost-effectiveness ratio for yearly screening beginning at ages 55 to 75 years ranged from $39 200 to $80 200/QALY. Yearly screening beginning at age 55 years was the optimal screening schedule in 38% of probabilistic uncertainty analysis simulations. The population EVPI, or value of reducing all uncertainty, was $8.2 to $12.6 billion varying with willingness to pay and the EVPPI, or value of reducing all screening effectiveness uncertainty, was $2.4 billion. CONCLUSIONS AND RELEVANCE: In this economic evaluation of US adult hearing screening, large uncertainty around the optimal adult hearing screening schedule was identified. Future research on hearing screening has a high potential value so is likely justified. American Medical Association 2022-11-11 /pmc/articles/PMC9652748/ /pubmed/36367737 http://dx.doi.org/10.1001/jamahealthforum.2022.4065 Text en Copyright 2022 Borre ED et al. JAMA Health Forum. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Borre, Ethan D. Myers, Evan R. Dubno, Judy R. Emmett, Susan D. Pavon, Juliessa M. Francis, Howard W. Ogbuoji, Osondu Sanders Schmidler, Gillian D. Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule |
title | Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule |
title_full | Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule |
title_fullStr | Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule |
title_full_unstemmed | Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule |
title_short | Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule |
title_sort | estimated monetary value of future research clarifying uncertainties around the optimal adult hearing screening schedule |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652748/ https://www.ncbi.nlm.nih.gov/pubmed/36367737 http://dx.doi.org/10.1001/jamahealthforum.2022.4065 |
work_keys_str_mv | AT borreethand estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule AT myersevanr estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule AT dubnojudyr estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule AT emmettsusand estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule AT pavonjuliessam estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule AT francishowardw estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule AT ogbuojiosondu estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule AT sandersschmidlergilliand estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule |